Everything below concerns reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Annie-Laurie Ala von Auersperg (born 1958), co-founder of the National Center for Victims of Crime, who married financier Ralph H. Isham, son of diplomat Heyward Isham. Alexander Georg von Auersperg (born 1959), co-founder of the National Center for Victims of Crime, who married investment banker Nancy Louise Weinberg. The Auerspergs were divorced in 1965. At that time, Sunny's net worth was over $75 million. Alfred Auersperg died in 1992 after lingering in an irreversible coma for nine years following a 1983 car accident in Austria. On June 6, 1966, Sunny married Claus von Bülow, a former aide to oilman J. P. Getty, at the Brick Presbyterian Church in New York City. His maternal grandfather, whose surname he took, was Frits Toxwerdt von Bülow, Justice Minister of Denmark in the government of Klaus Berntsen (1910–1913) and also came from a noble background. Together, they had a daughter:
On 1 July, the experiment was performed with fifty mice, half of whom received penicillin. All twenty-five of the control mice died within sixteen hours while all but one of the treated mice were alive ten days later. Over the following weeks they performed experiments with batches of 50 or 75 mice, but using different bacteria. They found that penicillin was also effective against staphylococci and gas gangrene. Florey reminded his staff that promising as their results were, a human being weighed 3,000 times as much as a mouse. The Oxford team reported their results in the 24 August 1940 issue of The Lancet, a prestigious medical journal, as "Penicillin as a Chemotherapeutic Agent" with names of the seven joint authors listed alphabetically. They concluded:
In 2012, Kahala signed a franchising deal with Phoenix-based America's Taco Shop. In 2013, a controlling interest in Kahala Corp. was purchased by the Serruya family of Canada. The Serruyas own and founded Yogen Früz, a chain with 1400 stores around the world. At that time, Michael Serruya became Chairman and Co-CEO of Kahala Corp. Shortly thereafter, Co-CEO Kevin Blackwell left the company. The Serruya family changed the company name from Kahala Corp to Kahala Brands to better align the focus of the business. In June 2015, Kahala Brands purchased Planet Smoothie and Tasti D-Lite. This acquisition added 128 new locations to the overall company store count and increased the total of smoothie-focused locations to over 400 worldwide. Just a few months later in November 2015, Kahala Brands purchased the gourmet coffee and smoothie brand Maui Wowi. At the time of the acquisition, Maui Wowi had with 400 mobile carts and 29 standalone retail units that operated by 200 franchisees. The following month, Kahala acquired Pinkberry in December. In July 2016, MTY Food Group Inc. of Montreal, Quebec in Canada purchased Kahala Brands for approximately US$310 million. Under the deal, Kahala remained in its headquarters in Scottsdale, Arizona while MTY's US operations was moved into Kahala's offices. Kahala's Chief Operating Officer Jeff Smit was chosen to lead the US operations of the combined entity.
== Function == Osteocalcin is secreted solely by osteoblasts and is thought to play a role in the body's metabolic regulation. In its carboxylated form, calcium is bound directly to the bone and thus concentrates here. In its uncarboxylated form, osteocalcin acts as a hormone in the body, signalling in the pancreas, fat, muscle, testes, and brain.
Sources: en.wikipedia.org
=== Bengali === Currently, the longest word in Bengali is the 33-letter-long আত্মশক্তিকরণেরসময়সীমাবদ্ধতার্থীয়তারপ্রতিবন্ধিতাক্ষরিতাবিশেষজ্ঞান, which translates to "The Boundary of Time for Self-Empowerment and Specialized Knowledge for its Corresponding Characters". Another long word often cited is the 11-letter-long অঘটনঘটনপটীয়সী, which means "one who is very skilled in doing unexpected things" or "skilled at unexpected incidents".
Similarly, thermostable proteins are rich in salt bridges or/and extra disulfide bridges stabilizing the structure. Other factors of protein thermostability are compactness of protein structure, oligomerization, and strength interaction between subunits.
Psilocybin's psychedelic effects can be blocked by serotonin 5-HT2A receptor antagonists like ketanserin and risperidone in humans. Activation of serotonin 5-HT2A receptors in layer V of the medial prefrontal cortex (mPFC) and consequent glutamate release in this area has been especially implicated in the hallucinogenic effects of psilocybin and other serotonergic psychedelics. In addition, region-dependent alterations in brain glutamate levels may be related to the experience of ego dissolution. The cryo-EM structures of the serotonin 5-HT2A receptor with psilocin, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues. Although serotonin 5-HT2A receptor agonism mediates the hallucinogenic effects of psilocybin and psilocin, activation of other serotonin receptors also appears to contribute to these compounds' psychoactive and behavioral effects. Serotonin 5-HT1A receptor activation seems to inhibit the hallucinogenic effects of psilocybin and other psychedelics. Some of psilocybin's non-hallucinogenic behavioral effects in animals can be reversed by antagonists of the serotonin 5-HT1A, 5-HT2B, and 5-HT2C receptors. Psilocybin produces profoundly decreased locomotor and investigatory behavior in rodents, and this appears to be dependent on serotonin 5-HT1A receptor activation but not on activation of the serotonin 5-HT2A or 5-HT2C receptors.
Sources: en.wikipedia.org
=== Genoa === In September 2021, 777 Partners bought 99.99% of Italian Serie A club Genoa CFC, the country's oldest club, founded in 1893. It became the sixth club in the league to have an American owner, and the transaction to buy the club from long-term owner Enrico Preziosi was estimated at €150 million. The club hired former AC Milan and Ukraine striker Andriy Shevchenko as the club manager in November, firing him in January 2022; Genoa ended the season relegated (as did another US-owned team, Venezia FC), but were immediately promoted back into the top division in May 2023. James Horncastle wrote in May 2024 that Genoa fans were not antagonistic toward 777, partly due to a history of mismanagement by Preziosi. Horncastle mentioned that Genoa had a one-point deduction for a late tax payment in their 2022–23 Serie B promotion season. On 18 December 2024, Genoa CFC announced that new majority stakeholder Dan Șucu, a Romanian businessman and owner of FC Rapid București and Mobexpert had taken over the club by paying €45m for 77% of the club. The following day, A-CAP released a statement advising that they still own the club, however, the board of Genoa CFC maintains that the sale is final.
In an investigative report published by The Insider news-outlet in 2024, journalist Yuriy Matsarsky stated:"...Captagon produced in underground labs—and in actual Syrian pharmaceutical facilities—is distributed to the fighters of Bashar Assad's army. Interestingly, however, the quantities the country produces far exceed its own military's demand. ... By some estimates, this business gives Syria more money than its entire legal export, and the regime constantly works to increase its profits, primarily by expanding its market reach. To this end, criminal gangs associated with Damascus or Hezbollah have built distribution networks for Captagon in countries where the drug was not previously popular."
== Scope and access == The CompTox Chemicals Dashboard database contains high quality chemical structures and information that have been extensively curated and quality checked, which can be used as a resource for analytical scientists involved in structure identification.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.